期刊文献+

评价CYFRA21-1、NSE和CEA对非小细胞肺癌的诊断价值 被引量:33

Evaluating the diagnostic values of serum CYFRA21-1,NSE and CEA levels determination in patients with non-small lung cancer
暂未订购
导出
摘要 目的评价血清CYFRA21-1、NSE和CEA对非小细胞肺癌(NSCLC)辅助诊断的价值。方法检测178例NSCLC患者,98例良性肺疾病(BLD)患者和166例健康人血清中CYFRA21-1、NSE和CEA的浓度,CEA采用微粒子酶联免疫化学发光法,NSE和CYFRA21-1采用电化学发光法。结果三项血清肿瘤标志物(TM)在NSCLC中水平显著高于健康人和BLD患者。以健康人为对照组,特异性95%时,cut off值分别为CYFRA21-1 2.23μg/L,CEA 3.98μg/L,NSE20.39μg/L。对NSCLC诊断灵敏度分别为CYFRA21-1 63.5%,CEA 47.8%,NSE 29.2%;以良性肺疾病为对照组,特异性95%时,cut off值分别为CYFRA21-1 3.26μg/L,CEA 5.51μg/L,NSE 26.14μg/L。对NSCLC灵敏度分别为CYFRA21-148.9%,CEA 39.3%,NSE 16.3%。CYFRA21-1对鳞癌的诊断灵敏度最高(66.2%),CEA对腺癌的诊断灵敏度最高(53.3%),NSE在非小细胞肺癌中也有一定的阳性率(13.0%-20.3%)。ROC曲线证实CYFRA21-1对良性肺疾病与非小细胞肺癌鉴别诊断价值最高。结论CYFRA21-1是诊断NSCLC尤其是鳞癌最有价值的TM,CEA对腺癌的诊断价值最高,CYFRA21-1和CEA联合显著提高NSCLC的诊断灵敏度。NSE对NSCLC的诊断价值较小。 Objective To evaluate the diagnostic values of serum CYFRA21-1, NSE and CEA levels determination in patients with non-small lung cancer (NSCLC) .Methods Serum concentrations of NSE,CEA and CYFRA21-1 were measured in 178 patients with NSCLC,98 patients with benign lung diseases (BID) and 166 healthy persons.CEA was measured by ebemiluminesent microparticle Immunoassay on ARCHITECT i2000sr. GYFRA21-1 and NSE were measured by electrocbemiluminescence immunoassays on the Roche Elecsys 2010. Results The serum concentrations of these three tumor markers were significandy higher in the NSCLC patients than in the healthy people and BLD patients When the healthy people were used as the reference group and the specificity was 95 %, the cutoff points of CYFRA 21-1 ,CEA and NSE were 2.23 μg/L,3.98μg/L and 20.39 μg/L respectively.At these points,the diagnostic sensitivities for NSCLC were CYFRA21-1 63.5% ,CEA 47.8% ,NSE 29.2% ,respectively.When the reference group was replaced with BLD patients,the cutoff points were elevated to 3.26μg/L,5.51 μg/L and 26.14μg/L respectively and the diagnostic sensitivities were reduced to 48.9 %, 16.3 % and 39.3 % respectively. For squamous cell carcinoma (SQC), CYFRA21-1 was the most sensitive tumor marker (66.2%) and so was CEA for adenocarcinoma (53.3%). The positive rates of NSE in the NSCLC ranged from 13.0% to 20.3% .Receiver operating curve demonstrated that CYFRA21-1 was the most valuable tumor marker for the differential diagnosis of BLD and NSCLC. Conclusion CYFRA 21-1 was of the most value for the diagnosis of NSCLC, especially squamous cell carcinoma. CEA was the most valuable tumor marker for adenocareinoma. There is little usefulness in diagnosing NSCLC for NSE.
出处 《中国实验诊断学》 北大核心 2009年第4期489-492,共4页 Chinese Journal of Laboratory Diagnosis
关键词 非小细胞肺癌 CYFRA21—1 NSE CEA non-small lung cancer CYFRA21-1 NSE CEA
  • 相关文献

参考文献5

  • 1Molina R, Filella X, Auge JM, et al. Tumor markers ( cea, ca 125, cyfra 21-1 ,scc and nse) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors[ J]. Tumour Biol, 2003,24 : 209.
  • 2Pastor A, Menendez R, Cremades M.I, et al. Diagnostic value of scc, cea and cyfra 21.1 in lung cancer: A bayesian analysis[J]. Eur Respir J, 1997,10:603.
  • 3Maeda T, Ueoka H, Tabata M, et al. Prognostic factors in advanced nonsmall cell lung cancer: Elevated serum levels of neuron specific enolase indicate poor prognosis[ J]. Jpn J Clin Oncol, 2000,30: 534.
  • 4Kulpa J, Wojcik E, Reinfuss M, et al. Carcinoembryonic antigen, squamous cell carcinoma antigen, cyfra 21-1, and neuron-specific enolase in squamous cell lung cancer patients[J]. Clin Chem,2002,48:1931.
  • 5Wieskopf B, Demangeat C, Purohit A, et al. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role[J]. Chest, 1995,108 : 163.

同被引文献345

引证文献33

二级引证文献236

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部